Clinigen Announces Keats Healthcare Integration and Outlines Ambitious Growth ...
22.05.12
Effective immediately, Keats Healthcare will become known as Clinigen
CTS and will be a dedicated Clinigen unit focused on sourcing and
supplying drugs for exclusive use in pharmaceutical customers’ clinical
studies. “Since the acquisition, we have clearly benefited from our
alignment with the Clinigen brand,” said Steven Campbell, vice-president
of Clinigen CTS. “Our expertise lies in the supply of comparator and
supportive drugs and we look forward to continuing this important work
as part of the broader Clinigen Group.”
The consolidation of Keats and its rebranding to Clinigen CTS reflects
Clinigen’s strategy of building a group of complementary businesses.
Clinigen CTS and Clinigen GAP, a provider of global access programs,
together make up Clinigen’s services division, led by Shaun Chilton, who
was appointed chief operating officer in January 2012.
“While providing standalone services, the Clinigen GAP and Clinigen CTS
teams have learnt that they can support each other,” said Mr Chilton.
“Clinical trial aftercare is often managed through compassionate use or
named patient programs. This is where Clinigen GAP can take over from
the work of Clinigen CTS, guaranteeing that patients will continue to
receive the treatments they need.”
Source: EON: Enhanced Online News (press release)